Pulmozyme is an innovative drug for the treatment of cystic fibrosis (CF). It improves the patient's respiratory function by reducing the accumulation of viscous mucus.
How to buy Dornase Alfa(Pulmozyme)
Dornase Alfa(Pulmozyme) is an imported drug that has not yet been launched in China. The purchase process is relatively complicated. The following is a detailed introduction to the purchase channels and precautions.
Purchase channels
Currently, the main purchase channels for Pulmozyme are overseas purchase or cross-border medical platforms. Since the drug has not been approved in China, regular domestic pharmacies and hospitals cannot provide it. Patients can obtain it through international pharmacies or professional purchase agencies, but it is necessary to make sure that the source of the drug is reliable to avoid counterfeit and inferior products.
Price and specifications
The specifications of this drug are 2.5mg/2.5mL*30 bottles. Due to additional costs such as transportation and tariffs, the actual price may be higher. Before purchasing, it is recommended to compare the prices and services of different channels and choose the most cost-effective method.
When purchasing Pulmozyme, you need to carefully choose the channel and clarify the quality of the drug. Next, we will explore its therapeutic effect.
Is the therapeutic effect of Dornase Alfa(Pulmozyme) good?
Pulmozyme has shown significant efficacy in the treatment of cystic fibrosis, especially in improving lung function.
Indications and mechanism of action
This drug is suitable for children and adults with cystic fibrosis. It reduces sputum viscosity by breaking down sticky DNA fragments, thereby improving respiratory function. Clinical studies have shown that it can effectively reduce the risk of respiratory tract infections and improve the quality of life of patients.
Clinical data support
In many clinical trials, patients using Pulmozyme have significantly improved lung function indicators and reduced the risk of FVC (forced vital capacity) decline. There are fewer adverse reactions, mainly mild symptoms such as voice changes and pharyngitis.
The therapeutic effect of Dornase Alfa(Pulmozyme) has been widely verified, so how is the patient's recognition of it?
Is the Pulmozyme highly recognized by patients?
Patients generally rate Pulmozymes highly, especially in terms of improving symptoms and quality of life.
Patient feedback
Many patients who have used the drug for a long time have reported that their breathing difficulties and sputum problems have been significantly reduced, and their ability to do daily activities has improved. Parents of child patients also said that their children's respiratory tract infections have decreased and their overall health has improved.
Evaluation of special populations
The safety of the drug for pregnant and lactating women has not been fully clarified, but existing data do not show obvious risks. The efficacy and safety of pediatric patients have been clinically confirmed, and there is less data for elderly patients.
Pulmozymes have won wide recognition from patients for their significant efficacy and safety. It is undoubtedly an important treatment option for patients with cystic fibrosis.
